Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ARArcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ Global Market · Currency in USD
$9.84 ▼ -0.89 (-8.29%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.03 ▲ +0.19 (+1.93%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$10.73
Open
$10.59
Day's Range
$9.75 – $10.69
52 Week Range
$5.50 – $17.96
Volume
474,929
Avg. Volume
831,509
Market Cap
$279.68M
Beta (5Y Monthly)
2.48
PE Ratio (TTM)
--
EPS (TTM)
-$3.28
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Jan 8, 2013
1y Target Est
$30.50

Profile: Arcturus Therapeutics Holdings Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
109
CEO
Joseph E. Payne

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.69 · Revenue est. $8.00M
DateEst.Actual
Aug 6, 2026-$1.00-$0.84Beat
May 7, 2026-$1.03-$0.95Beat
Mar 3, 2026-$0.92-$1.03Miss
Nov 10, 2025-$0.80-$0.49Beat
Aug 11, 2025-$0.89-$0.34Beat
May 12, 2025-$1.58-$0.52Beat

Analyst view

Consensus price target
$30.50 ▲ +210.0%
Range $20.00 – $41.00
Rating: Buy
Buy 57% · Hold 24% · Sell 19%

Get free alerts on ARCT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.